Dr. da Cruz has more than 16 years of experience in therapeutic antibody discovery and development, having led projects as a scientist and in management responsibilities, both in antibody and drug development from discovery to late clinical stage. Dr. da Cruz initiated his career as a Product Development scientist at MDS-SCIEX, in the development of label-free technologies for drug discovery.
After he worked as Senior Scientist at Arius Research Inc. responsible for the identification of cancer targets and in the pre-clinical scientific leadership of multiple cancer therapeutic antibody. Upon acquisition of Arius Research Inc. by Roche Pharmaceuticals, Dr. da Cruz worked as Principal Scientist at Hoffman La-Roche continuing his previous work in early antibody discovery and supporting the late preclinical development and early clinical development of an anti-CD44 monoclonal antibody for treatment of AML.  Upon departure from Roche Pharmaceuticals, Dr. da Cruz worked as Senior Scientist at Astellas/Agensys in the discovery and development of biomarker strategies supporting the clinical development of ADCs. After, he worked as a Senior Clinical scientist at Boehringer Ingelheim Canada, Ltd in the operational management of Phase III clinical trials for diabetes and Oncology, the latter supporting the development and approval of the TKI Affatinib for use in the therapy of NSCLC.

Dr. da Cruz holds a B.Sc. and a Ph.D. in Biochemistry from the University of Coimbra, Portugal and completed his post-doctoral training at the Samuel Lunenfeld Institute, Mount Sinai Hospital in Toronto, in the molecular and cellular Immunology of B cell development and function.

• 

  Vice President, Research in Kisoji

  Breakthrough antibody discovery for breakthrough therapeutics